Tags

Type your tag names separated by a space and hit enter

Dyslipidemia in patients with chronic kidney disease.
Rev Endocr Metab Disord. 2017 03; 18(1):29-40.RE

Abstract

Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.

Authors+Show Affiliations

Department of Internal Medicine University of Kentucky, Lexington, KY, USA.Division of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA.Division of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA. Lisa.Tannock@uky.edu. Department of Veterans Affairs, Lexington, KY, USA. Lisa.Tannock@uky.edu. University of Kentucky, 900 S. Limestone, Room 553 CTW, Lexington, KY, 40536-0200, USA. Lisa.Tannock@uky.edu.

Pub Type(s)

Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

28000009

Citation

Hager, Matthew R., et al. "Dyslipidemia in Patients With Chronic Kidney Disease." Reviews in Endocrine & Metabolic Disorders, vol. 18, no. 1, 2017, pp. 29-40.
Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18(1):29-40.
Hager, M. R., Narla, A. D., & Tannock, L. R. (2017). Dyslipidemia in patients with chronic kidney disease. Reviews in Endocrine & Metabolic Disorders, 18(1), 29-40. https://doi.org/10.1007/s11154-016-9402-z
Hager MR, Narla AD, Tannock LR. Dyslipidemia in Patients With Chronic Kidney Disease. Rev Endocr Metab Disord. 2017;18(1):29-40. PubMed PMID: 28000009.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dyslipidemia in patients with chronic kidney disease. AU - Hager,Matthew R, AU - Narla,Archana D, AU - Tannock,Lisa R, PY - 2016/12/22/pubmed PY - 2017/5/11/medline PY - 2016/12/22/entrez KW - Cardiovascular disease KW - Cholesterol KW - Chronic kidney disease KW - Lipids KW - Renal KW - Statins SP - 29 EP - 40 JF - Reviews in endocrine & metabolic disorders JO - Rev Endocr Metab Disord VL - 18 IS - 1 N2 - Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD. SN - 1573-2606 UR - https://www.unboundmedicine.com/medline/citation/28000009/Dyslipidemia_in_patients_with_chronic_kidney_disease_ L2 - https://doi.org/10.1007/s11154-016-9402-z DB - PRIME DP - Unbound Medicine ER -